Immunotherapy combo tested in rare, Tough-to-Treat kidney cancer
NCT ID NCT03274258
Summary
This study tested whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, could help control an aggressive and rare form of kidney cancer called renal medullary carcinoma. The trial involved 10 patients with advanced cancer that had spread or could not be surgically removed. The goal was to see if these drugs, which help the body's own immune system fight cancer, could shrink tumors and slow the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.